Effects of Donepezil,Galantamine and Rivastigmine in 938 Italian Patients with Alzheimer’s Disease
暂无分享,去创建一个
C. Franceschi | S. Sorbi | B. Nacmias | W. Gianni | L. Grimaldi | G. Binetti | F. Marchegiani | L. Benussi | R. Ghidoni | P. Siviero | S. Bagnoli | G. Crepaldi | A. Iorio | A. Ginestroni | A. Santoro | M. Mishto | E. Bellavista | C. Gabelli | E. Feraco | F. Olivieri | R. Paganelli | N. Minicuci | M. Scognamiglio | O. Scarpino | A. Chiamenti | G. Cruciani | Luigi Maria Edoardo Grimaldi
[1] H. Soininen,et al. Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients. , 2009, Current Alzheimer research.
[2] D. Yang,et al. Effect of ApoE Genotype on Response to Donepezil in Patients with Alzheimer’s Disease , 2008, Dementia and Geriatric Cognitive Disorders.
[3] P. Raina,et al. Effectiveness of Cholinesterase Inhibitors and Memantine for Treating Dementia: Evidence Review for a Clinical Practice Guideline , 2008, Annals of Internal Medicine.
[4] M. Lai,et al. How long can patients with mild or moderate Alzheimer’s dementia maintain both the cognition and the therapy of cholinesterase inhibitors: a national population‐based study , 2008, European journal of neurology.
[5] B. Winblad,et al. A rivastigmine patch for the treatment of Alzheimer’s disease and Parkinson’s disease dementia , 2007, Expert review of neurotherapeutics.
[6] A. Cedazo-Mínguez,et al. Apolipoprotein E and Alzheimer's disease: molecular mechanisms and therapeutic opportunities , 2007, Journal of cellular and molecular medicine.
[7] Marek Bajda,et al. Recent developments in cholinesterases inhibitors for Alzheimer's disease treatment. , 2007, Current medicinal chemistry.
[8] J. Touchon,et al. Six and 18-month changes in mild to moderate Alzheimer's patients treated with acetylcholinesterase inhibitors: what can we learn for clinical outcomes of therapeutic trials? , 2007, The journal of nutrition, health & aging.
[9] N. Relkin. Beyond symptomatic therapy: a re-examination of acetylcholinesterase inhibitors in Alzheimer’s disease , 2007, Expert review of neurotherapeutics.
[10] B. Winblad,et al. A six‐month double‐blind, randomized, placebo‐controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patch versus capsule , 2007, International journal of geriatric psychiatry.
[11] H. Feldman,et al. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer’s disease , 2007, Journal of Neurology, Neurosurgery, and Psychiatry.
[12] M. Boada,et al. Relationship Between the Efficacy of Rivastigmine and Apolipoprotein E (ϵ4) in Patients With Mild to Moderately Severe Alzheimer Disease , 2006, Alzheimer disease and associated disorders.
[13] Sture Eriksson,et al. Donepezil in patients with severe Alzheimer's disease: double-blind, parallel-group, placebo-controlled study , 2006, The Lancet.
[14] B. Kee,et al. Effect of the Apolipoprotein E ε4 Allele on the Efficacy and Tolerability of Galantamine in the Treatment of Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.
[15] C. Marra,et al. Apolipoprotein E ε4 Allele Differentiates the Clinical Response to Donepezil in Alzheimer’s Disease , 2005, Dementia and Geriatric Cognitive Disorders.
[16] Hendrik van den Bussche,et al. Cholinesterase inhibitors for patients with Alzheimer's disease: systematic review of randomised clinical trials , 2005, BMJ : British Medical Journal.
[17] M. Maggini,et al. A cohort study of effectiveness of acetylcholinesterase inhibitors in Alzheimer’s disease , 2005, European Journal of Clinical Pharmacology.
[18] David Ames,et al. Metaanalysis of randomized trials of the efficacy and safety of donepezil, galantamine, and rivastigmine for the treatment of Alzheimer disease. , 2004, The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry.
[19] M. Petrovecki,et al. ApoE genotyping and response to galanthamine in Alzheimer's disease--a real life retrospective study. , 2004, Collegium antropologicum.
[20] K. Rockwood,et al. Size of the treatment effect on cognition of cholinesterase inhibition in Alzheimer’s disease , 2004, Journal of Neurology, Neurosurgery & Psychiatry.
[21] Roy W Jones,et al. A multinational, randomised, 12‐week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease , 2004, International journal of geriatric psychiatry.
[22] T. Einarson,et al. Efficacy and safety of cholinesterase inhibitors in Alzheimer's disease: a meta-analysis. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[23] R. Bullock,et al. A MULTINATIONAL, RANDOMISED, 12‐WEEK, COMPARATIVE STUDY OF DONEPEZIL AND RIVASTIGMINE IN PATIENTS WITH MILD TO MODERATE ALZHEIMER'S DISEASE , 2002, International journal of clinical practice.
[24] R. Mohs,et al. Consortium to establish a registry for Alzheimer's disease (CERAD) clinical and neuropsychological assessment of Alzheimer's disease. , 2002, Psychopharmacology bulletin.
[25] G. Wilcock,et al. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial , 2000, BMJ : British Medical Journal.
[26] E. Peskind,et al. Galantamine in AD , 2000, Neurology.
[27] G. Wilcock,et al. Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease , 1998, International journal of geriatric psychiatry.
[28] M. Mega,et al. The Neuropsychiatric Inventory , 1994, Neurology.
[29] K. Davis,et al. A longitudinal study of Alzheimer's disease: measurement, rate, and predictors of cognitive deterioration. , 1994, The American journal of psychiatry.
[30] A. Heyman,et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1993, Neurology.
[31] D. T. Vernier,et al. Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI. , 1990, Journal of lipid research.
[32] K. Davis,et al. A new rating scale for Alzheimer's disease. , 1984, The American journal of psychiatry.
[33] M. Folstein,et al. Clinical diagnosis of Alzheimer's disease , 1984, Neurology.
[34] S. Folstein,et al. “Mini-mental state”: A practical method for grading the cognitive state of patients for the clinician , 1975 .
[35] M. Lawton,et al. Assessment of older people: self-maintaining and instrumental activities of daily living. , 1969, The Gerontologist.
[36] S. Katz,et al. STUDIES OF ILLNESS IN THE AGED. THE INDEX OF ADL: A STANDARDIZED MEASURE OF BIOLOGICAL AND PSYCHOSOCIAL FUNCTION. , 1963, JAMA.
[37] J. Birks. Cholinesterase inhibitors for Alzheimer's disease. , 2006, The Cochrane database of systematic reviews.
[38] G. Masotti,et al. Effectiveness and safety of cholinesterase inhibitors in elderly subjects with Alzheimer's disease: a "real world" study. , 2004, Archives of gerontology and geriatrics. Supplement.
[39] S. Kudaravalli,et al. Differential qualitative responses to rivastigmine in APOE ɛ4 carriers and noncarriers , 2004, The Pharmacogenomics Journal.
[40] F. Campana,et al. Alzheimer's disease and acetylcholinesterase inhibitor agents: a two-year longitudinal study. , 2004, Archives of gerontology and geriatrics. Supplement.
[41] Luc Truyen,et al. A Long-Term Comparison of Galantamine and Donepezil in the Treatment of Alzheimer’s Disease , 2003, Drugs & aging.
[42] Jeroen Aerssensa Peter Raeymaekersa Sean Lilienfeldb Hugo Geertsc,et al. APOE Genotype : No Influence on Galantamine Treatment Efficacy Nor on Rate of Decline in Alzheimer ’ s Disease , 2001 .
[43] S. Katz. Studies of illness in the aged , 1963 .